psoriatic disease
Recently Published Documents


TOTAL DOCUMENTS

279
(FIVE YEARS 123)

H-INDEX

23
(FIVE YEARS 6)

Author(s):  
O. B. Nemchaninova ◽  
E. Yu. Sklyanova ◽  
S. G. Lykova ◽  
E. N. Makhnovets ◽  
O. N. Pozdnyakova ◽  
...  

Non-alcoholic fatty liver disease (NAFLD), being a marker of significant changes in the hepatobiliary system against the background of metabolic syndrome and other endocrine pathologies, has a significant impact on the course of psoriatic disease. The presence of common mechanisms in the pathogenesis of these diseases suggests a very close relationship between them. This requires a multidisciplinary approach to studying the mechanisms of the pathogenesis of psoriasis and NAFLD, which will improve the methods of diagnosis and treatment of both diseases.


2021 ◽  
pp. 247553032110678
Author(s):  
George C. Gondo ◽  
Megan H. Noe ◽  
Stacie J. Bell ◽  
Christopher T. Ritchlin

Introduction: Development and dissemination of novel COVID-19 vaccines represent an opportunity to end the COVID-19 pandemic by vaccinating an estimated 80% of the population. Objectives: This study examines perceptions, and demographic and clinical factors influencing the likelihood of adults with psoriasis receiving a novel COVID-19 vaccine. Methods: A cross sectional study conducted from October–November 2020 of 1405 adults with psoriatic disease with prior contact to a patient advocacy organization. The main outcome of interest was the likelihood of receiving a COVID-19 vaccine. Chi-square tests and logistic regression examined the relationship between individual characteristics and likelihood of receiving a COVID-19 vaccine. Results: Most participants (65%) received a flu vaccination in the last 12 months and were (64.2%) likely to receive a COVID-19 vaccine, while 35.9% reported being unlikely receive a vaccine. Likelihood of COVID-19 vaccination was associated with receiving the flu vaccine, race, ethnicity, sex, BMI, age, income, severity of PsO and PsA. When controlling for ethnicity, race, male sex, overweight/obese status, age, biologic use, disease type, comorbidities linked with worse COVID-19 outcomes, PsA symptoms, and skin disease severity, individuals who received the flu vaccine and those with annual household income over $75,000 were most likely to receive a COVID-19 vaccine. Conclusions: Vaccine hesitancy among individuals with psoriatic disease is considerable. Dermatologists and rheumatologists can increase COVID-19 vaccine uptake by actively engaging their patients on this topic using guidance published by the National Psoriasis Foundation on the management of psoriatic disease during the COVID-19 pandemic.


2021 ◽  
Vol 22 (23) ◽  
pp. 13004
Author(s):  
Rubén Queiro ◽  
Pablo Coto-Segura ◽  
Leire González-Lara ◽  
Eliecer Coto

Psoriasis is a multifactorial genetic disease for which the genetic factors explain about 70% of disease susceptibility. Up to 30–40% of psoriasis patients develop psoriatic arthritis (PsA). However, PsA can be considered as a “disease within a disease”, since in most cases psoriasis is already present when joint complaints begin. This has made studies that attempt to unravel the genetic basis for both components of psoriatic disease enormously difficult. Psoriatic disease is also accompanied by a high burden of comorbid conditions, mainly of the cardiometabolic type. It is currently unclear whether these comorbidities and psoriatic disease have a shared genetic basis or not. The nuclear factor of kappa light chain enhancer of activated B cells (NF-κB) is a transcription factor that regulates a plethora of genes in response to infection, inflammation, and a wide variety of stimuli on several cell types. This mini-review is focused on recent findings that highlight the importance of this pathway both in the susceptibility and in the determinism of some features of psoriatic disease. We also briefly review the importance of genetic variants of this pathway as biomarkers of pharmacological response. All the above may help to better understand the etiopathogenesis of this complex entity.


Author(s):  
Sotirios G. Tsiogkas ◽  
Αthanasios Mavropoulos ◽  
Dimitrios N. Skyvalidas ◽  
Eleni Patrikiou ◽  
Niki Ntavari ◽  
...  

Author(s):  
Matteo Vecellio ◽  
Elvezia Maria Paraboschi ◽  
Angela Ceribelli ◽  
Natasa Isailovic ◽  
Francesca Motta ◽  
...  

Background: Psoriatic disease is a multifactorial inflammatory condition spanning from skin and nail psoriasis (Pso) to spine and joint involvement characterizing psoriatic arthritis (PsA). Monozygotic twins provide a model to investigate genetic, early life environmental exposure and stochastic influences to complex diseases, mainly mediated by epigenetics.Methods: We performed a genome-wide DNA methylation study on whole blood of monozygotic twins from 7 pairs discordant for Pso/PsA using the Infinium Methylation EPIC array (Illumina). MeDiP—qPCR was used to confirm specific signals. Data were replicated in an independent cohort of seven patients with Pso/PsA and 3 healthy controls. Transcriptomic profiling was performed by RNAsequence on the same 7 monozygotic twin pairs.Results: We identified 2,564 differentially methylated positions between psoriatic disease and controls, corresponding to 1,703 genes, 59% within gene bodies. There were 19 regions with at least two DMPs within 1 kb of distance and significant within-pair Δβ-values (p < 0.005), among them SNX25, BRG1 and SMAD3 genes, all involved in TGF-β signaling pathway, were identified. Co-expression analyses on transcriptome data identified IL-6/JAK/STAT3 and TNF-α pathways as important signaling axes involved in the disease, and they also suggested an altered glucose metabolism in patients’ immune cells, characteristic of pro-inflammatory T lymphocytes.Conclusion: The study suggests the presence of an epigenetic signature in affected individuals, pointing to genes involved in immunological and inflammatory responses. This result is also supported by transcriptome data, that altogether suggest a higher activation state of the immune system, that could promote the disease status.


2021 ◽  
Author(s):  
Adriana Denisse García Coello

PANLAR collected feedback and recommendations from patients and expert rheumatologists on the unmet needs of those diagnosed with psoriatic disease and set them down in a position paper


2021 ◽  
Vol 8 ◽  
Author(s):  
Fei Qi ◽  
Yaqi Tan ◽  
Amin Yao ◽  
Xutong Yang ◽  
Yanling He

Psoriatic disease (PsD) is a spectrum of diseases that affect both skin [cutaneous psoriasis (PsC)] and musculoskeletal features [psoriatic arthritis (PsA)]. A considerable number of patients with PsC have asymptomatic synovio-entheseal inflammations, and approximately one-third of those eventually progress to PsA with an enigmatic mechanism. Published studies have shown that early interventions to the very early-stage PsA would effectively prevent substantial bone destructions or deformities, suggesting an unmet goal for exploring early PsA biomarkers. The emergence of proteomics technologies brings a complete view of all involved proteins in PsA transitions, offers a unique chance to map all potential peptides, and allows a direct head-to-head comparison of interaction pathways in PsC and PsA. This review summarized the latest development of proteomics technologies, highlighted its application in PsA biomarker discovery, and discussed the possible clinical detectable PsA risk factors in patients with PsC.


Author(s):  
Svetlana G. Makarova ◽  
Irina Yu. Pronina

In the pathogenesis of the psoriatic disease, genetic and environmental factors play a significant role, and one of the most critical ecological influences is nutrition. At the same time, the influence of nutrition on the pathogenetic links of psoriasis is currently underestimated. The clinical guidelines for managing children and adults with psoriasis do not mention the need to consult a nutritionist and any dietary recommendations. The purpose of this literature review was to analyze current data on the role of various nutritional factors in the development of psoriatic disease, the pathogenesis of its complicated course, as well as the effectiveness of dietary interventions in the treatment of this category of patients. The analysis of sixty eight sources of literature has shown that dietary changes and the use of biologically active food supplements can have a specific effect on the complex therapy of the disease. The possibilities of diet therapy in patients with psoriasis and metabolic syndrome are also discussed. At the same time, it is evident that further research is needed to improve the evidence base for the effectiveness of nutritional methods in managing this category of patients, especially in paediatric-age patients.


Sign in / Sign up

Export Citation Format

Share Document